December 17th 2021
Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.
November 2nd 2021
Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.
September 22nd 2021
Joleen M. Hubbard, MD, discusses the barriers of implementing circulating tumor DNA into widespread clinical practice in colorectal cancer.
August 24th 2021
John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.
The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.
August 17th 2021
Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.
Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.
August 10th 2021
Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.
Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.
August 3rd 2021
Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.
Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.
July 27th 2021
Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.
Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.
July 1st 2021
Joleen M. Hubbard, MD, discusses the utility of minimal residual disease assessment for stage II colorectal cancer.
May 28th 2021
Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.
Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.
May 21st 2021
Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.
Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.
May 18th 2021
Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.